Dr. Tripathy on Combination Strategies With CDK4/6 Inhibitors in HR+ Breast Cancer
September 10th 2018
Debu Tripathy, MD, professor and chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses combination strategies with CDK4/6 inhibitors for the treatment of patients with hormone receptor (HR)-positive breast cancer.